Integra Therapeutics will present positive data from ex vivo and in vivo preclinical studies that demonstrates the potential of its FiCAT gene writing platform for developing advanced therapies in the field of paediatric hepatology at the Advanced Therapies Europe congress, taking place in Estoril (Portugal) from 5 to 7 September.
Dr Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics, will analyse the data in a conference titled FiCAT Innovative Gene Writing Platform for Advanced Therapies on 7 September at 10:30 am local time, as part of a panel on innovative technologies as a driving force for successful commercialisation of cell and gene therapies on the European market.
Backed by a team of talented researchers, Integra Therapeutics has built a solid technology platform that can write large and small genes, combining the precision of the CRISPR-Cas9 technique and the efficient cargo transfer of a programmable PiggyBac transposon. FiCAT has been tested for ex vivo cell engineering and in vivo gene therapy.
“The ex vivo and in vivo preclinical data validates our FiCAT gene-writing platform for developing cell and gene therapies for patients with genetic minority and oncological diseases and is driving us to intensify our efforts to move into the preclinical regulatory phase in the coming months,” explains Avencia Sánchez-Mejías.
The company continues to expand FiCAT with tools like more effective alternative transposons and programmable nucleases thanks to its high-performance system to detect improved genome editors, along with protein design using artificial intelligence, in order to make gene writing safer and more flexible, efficient and broadly applicable.